Compare CPF & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CPF | ENGN |
|---|---|---|
| Founded | 1954 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 802.1M | 647.1M |
| IPO Year | 2011 | N/A |
| Metric | CPF | ENGN |
|---|---|---|
| Price | $33.83 | $7.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $37.00 | $21.08 |
| AVG Volume (30 Days) | 109.1K | ★ 370.1K |
| Earning Date | 04-29-2026 | 06-11-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 45.18 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $51,817,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.62 | N/A |
| P/E Ratio | $42.65 | ★ N/A |
| Revenue Growth | ★ 33.81 | N/A |
| 52 Week Low | $25.62 | $2.66 |
| 52 Week High | $35.41 | $12.25 |
| Indicator | CPF | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 43.67 |
| Support Level | $33.25 | $6.15 |
| Resistance Level | $35.03 | $7.33 |
| Average True Range (ATR) | 0.80 | 0.57 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 31.49 | 19.21 |
Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services. It operates in single segment which is Banking operations.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.